





# Advances in Neurofibromatosis

INTEGRATING MULTI-MODALITY THERAPY



## OVERVIEW

MSK CME is pleased to offer an on demand option for ***Advances in Neurofibromatosis: Integrating Multi-modality Therapy***, which was recorded Friday, October 9, 2020.

The on demand registration fee will include access to the video recording from the one-day course as well as an online syllabus (PDFs of the presentations).

CME credit is available for the on demand program; access details credit instructions are included in the registration confirmation email.

**This program is intended to provide an update on current evaluation and multi-modality therapy for neurofibromatosis.**

Neurofibromatosis represents a group of inheritable disorders that require multi-disciplinary integrated care. Major advances in defining molecular alterations and developing targeted therapies have changed the landscape of treatment, but require continued laboratory and clinical investigations.

Clinicians and scientists at Memorial Sloan Kettering Cancer Center (MSK) are pursuing numerous areas of investigation in the clinic and laboratory and we anticipate will become one of the driving forces in the development of newer therapies for both benign and malignant tumors (eg MPNST) in NF-associated tumors. Additionally, MSK is one of the most active surgical groups in the world with the recent integration of advanced technologies such as DaVinci robot resection of paraspinal benign tumors.

## MSK COURSE DIRECTORS



**Mark Bilsky, MD**

Attending Neurosurgeon  
Chief, Multi-Disciplinary Spine Tumor Service



**Matthias Karajannis, MD, MS**

Chief, Pediatric Neuro-Oncology Service



**Ori Barzilai, MD**

Assistant Attending Neurosurgeon



**Anna Piotrowski, MD**

Assistant Attending Neuro-Oncologist

## MSK COURSE FACULTY

**Edmund Bartlett, MD**

Assistant Attending Surgeon

**Aimee Crago, MD, PhD**

Associate Attending Surgeon

**Amitabh Gulati, MD**

Associate Attending Physician  
Director, Chronic Pain

**Jonathan Landa, DO**

Associate Attending Radiologist

**Daniel Prince, MD, MPH**

Assistant Attending Surgeon

**Samuel Selesnick, MD**

Attending Surgeon (WCMC, MSK)  
Vice Chairman, Department of Otolaryngology -  
Head & Neck Surgery

**William Tap, MD**

Chief, Sarcoma Medical Oncology Service

**Michael Walsh, MD**

Assistant Attending Geneticist and  
Pediatric Oncologist

**Yoshiya (Josh) Yamada, MD**

Attending Radiation Oncologist

# SESSIONS

## SESSION I • NF1/MPNST

MODERATOR: Matthias Karajannis, MD, MS

10 MIN.	<b>Welcome &amp; Session I Introduction</b> • Mark Bilsky, MD
15 MIN.	<b>Genetics of NF1</b> • Michael Walsh, MD
15 MIN.	<b>Imaging of NF1</b> • Jonathan Landa, DO
20 MIN.	<b>NF1 Targeted Therapy</b> • Anna Piotrowski, MD
10 MIN.	<b>Clinical Trials for MPNST</b> • William Tap, MD
20 MIN.	<b>Surgical Management for MPNST</b> • Edmund Bartlett, MD
20 MIN.	<b>NF1-associated Tumors (GIST, Breast)</b> • Aimee Crago, MD, PhD
20 MIN.	<b>Management of Long Bone Dysplasias</b> • Daniel Prince, MD, MPH
30 MIN.	<b>TUMOR BOARD</b>  <b>CASE PRESENTERS</b> Aimee Crago, MD, PhD Edmund Bartlett, MD  <b>PANELISTS</b> Mark Bilsky, MD William Tap, MD, Yoshiya (Josh) Yamada, MD

## SESSION II • NF2/Schwannomatosis

MODERATOR: Anna Piotrowski, MD

5 MIN.	<b>Session II Introduction</b> • Mark Bilsky, MD
15 MIN.	<b>Genetics of NF2/Schwannomatosis</b> • Michael Walsh, MD
15 MIN.	<b>Imaging of NF2/Schwannomatosis</b> • Jonathan Landa, DO
20 MIN.	<b>Surgical Management of Vestibular Schwannomas</b> • Samuel Selesnick, MD
20 MIN.	<b>Molecular Targeted Therapies for NF2</b> • Matthias Karajannis, MD, MS
15 MIN.	<b>Advances in Spine Surgery for Neurofibromatosis</b> • Ori Barzilai, MD
10 MIN.	<b>The Role of Radiation Therapy in NF</b> • Yoshiya (Josh) Yamada, MD
20 MIN.	<b>Pain Management</b> • Amitabh Gulati, MD
30 MIN.	<b>TUMOR BOARD</b>  <b>CASE PRESENTER</b> Matthias Karajannis, MD, MS  <b>PANELISTS</b> Anna Piotrowski, MD Samuel Selesnick, MD, Yoshiya (Josh) Yamada, MD
10 MIN.	<b>Closing Remarks</b> • Anna Piotrowski, MD

# REGISTER ONLINE

## [mskcc.org/neurofibromatosisonline](https://mskcc.org/neurofibromatosisonline)

### On Demand Registration Fees

Physicians (MDs, PhDs and DOs)	\$75
Advanced Practice Providers (NPs and PAs)	\$50
Residents, Fellows, Nurses, and Other Healthcare Providers:	\$50
Industry Professionals*	\$130

\*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

By registering for this on demand program, you will receive access to videos of the 14 lectures and 2 tumor boards from the course, which was originally recorded on October 9, 2020, as well as PDFs of the speaker presentations.

This on demand program will be available for purchase until **May 31, 2021**. Access to the videos and claiming credit will be available until **April 30, 2022**.

### Registration Discounts/Promotions

- MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners. If you are a member of one of these groups, please contact [cme@mskcc.org](mailto:cme@mskcc.org) for more information.
- MSK employee registration is complimentary. However, you must complete course registration in order to attend this course.

For additional information and registration details, visit the course website: [mskcc.org/neurofibromatosisonline](https://mskcc.org/neurofibromatosisonline)

## ACCREDITATION

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **5.50 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.



Memorial Sloan Kettering  
Cancer Center



MSK CME  
**ON DEMAND**

# Advances in Neurofibromatosis:

INTEGRATING MULTI-MODALITY THERAPY

[mskcc.org/neurofibromatosisonline](https://mskcc.org/neurofibromatosisonline)



Memorial Sloan Kettering  
Cancer Center